An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Axonics® Announces Partial Decision on Inter Partes Review Proceedings
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary
Axonics (NASDAQ: AXNX) announced that the U.S. Patent Trial and Appeal Board (PTAB) issued final decisions on three of six patents from Medtronic that Axonics contests. The PTAB invalidated four claims of the '069 Patent while upholding claims of the '314 and '756 Patents, which will expire in 2022. Axonics plans to appeal the upheld claims but emphasizes that the decisions do not imply patent infringement. This outcome is viewed as a significant victory for Axonics, reflecting the strength of their arguments against Medtronic's claims.
Positive
PTAB invalidated four of five claims of the '069 Patent, a significant win for Axonics.
The decision reinforces Axonics' legal position against Medtronic.
Plans to appeal the PTAB's decision indicate continued commitment to defend its interests.
Negative
Three claims from Medtronic's patents remain upheld, which could affect Axonics' operations.
Uncertainty remains as further appeals may take time and resources.
IRVINE, Calif.--(BUSINESS WIRE)--
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued final written decisions on three of the six Medtronic patents that Axonics is contesting.
In March 2020, Axonics filed petitions with the PTAB requesting inter partes review (IPR) to contest the validity of patents Medtronic has alleged to be infringed by Axonics. In September 2020, the PTAB granted Axonics’ request and instituted a review of the following six Medtronic patents: Nos. 7,774,069; 8,626,314; 8,036,756; 8,457,758; 8,738,148; and 9,821,112.
Today, the PTAB issued its decision with respect to Patent Nos. 7,774,069 (the “’069 Patent”); 8,626,314 (the “’314 Patent), and 8,036,756 (the “’756 Patent”). Decisions are still pending on the remaining three patents.
The PTAB agreed with Axonics on four of the five claims Axonics is contesting in the ‘069 Patent, holding that those four claims are invalid and unpatentable. In addition, the PTAB upheld the nearly expired claims in the ‘756 Patent and the ‘314 Patent. The ‘756 Patent expires on November 9, 2021, and the ‘314 Patent expires on February 18, 2022.
Axonics plans to appeal the PTAB’s decisions on the claims it declined to invalidate to the Director of the Patent & Trademark Office and to the U.S. Court of Appeals for the Federal Circuit. The PTAB’s decision only relates to the issue of invalidity or patentability of the Medtronic patents and does not mean that Axonics infringes any of the patents.
“We are quite pleased with the PTAB’s decision to invalidate four of the five key claims of the ‘069 Patent, which reflects the merit of the compelling arguments we presented and represents a significant victory for Axonics,” said Raymond W. Cohen, chief executive officer of Axonics. “We respectfully disagree with the PTAB’s decision on the claims it declined to invalidate, and we intend to appeal. It’s also important to understand that the PTAB rulings are not related to the notion of infringement – they are simply addressing whether or not the claims in these patents are valid as a starting point. We are confident that we will ultimately prevail on all of the patent claims Medtronic has asserted against us.”
About Axonics
Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for patients with bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid®, provides women suffering from stress urinary incontinence (SUI) with safe and durable symptom relief.
Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.
Forward-Looking Statements
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.
Axonics contact:
Neil Bhalodkar Investor Relations
949-336-5293
ir@axonics.com
Source: Axonics, Inc.
FAQ
What did Axonics announce regarding Medtronic patents?
Axonics announced that the PTAB ruled on three Medtronic patents, invalidating four claims of the '069 Patent and upholding claims of the '314 and '756 Patents.
When did Axonics file petitions against Medtronic patents?
Axonics filed petitions with the PTAB in March 2020, initiating a review of six Medtronic patents.
What is the status of Axonics' appeal on PTAB decisions?
Axonics plans to appeal the PTAB's decisions regarding the upheld claims to the Director of the Patent & Trademark Office and the U.S. Court of Appeals for the Federal Circuit.
What implications does the PTAB decision have for Axonics?
The PTAB's decision is a significant victory for Axonics as four claims of the '069 Patent were invalidated, but uncertainty remains due to three upheld claims.
What patents did the PTAB issue decisions on?
The PTAB issued decisions on Patent Nos. 7,774,069, 8,626,314, and 8,036,756, with claims upheld in the latter two patents.
